Activating somatic JAK2 mutations were reported in 20% of DS ALL patients and nearly all of the JAK2 point mutations happened at a common site, an arginine-to-guanine residue at position 683 (A683G) [66]. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.